Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanna Finocchiaro

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Clinical Lung Cancer|August 15, 2019
Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant ChemotherapyAngelo Castello, Luca Toschi, Sabrina Rossi, et al.
Expert Review of Anticancer Therapy|December 22, 2022
Current treatment approaches for brain metastases in <i>ALK</i>/<i>ROS1</i>/<i>NTRK</i>-positive non-small-cell lung cancerSabrina Rossi, Arianna Marinello, Arianna Pagliaro, et al.
Nuclear Medicine Communications|April 3, 2018
Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancerAngelo Castello, Fabio Grizzi, Luca Toschi, et al.
Current Problems in Cancer|September 7, 2021
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLCSabrina Rossi, Paola Damiano, Luca Toschi, et al.
Cancers|December 23, 2023
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?Sabrina Rossi, Arianna Pagliaro, Angelica Michelini, et al.
Cancers|September 10, 2021
Subpopulations of Circulating Cells with Morphological Features of Malignancy Are Preoperatively Detected and Have Differential Prognostic Significance in Non-Small Cell Lung CancerEmanuela Fina, Davide Federico, Pierluigi Novellis, et al.
Critical Reviews in Oncology/Hematology|March 15, 2006
Clinical experience with gefitinib: an updateFederico Cappuzzo, Giovanna Finocchiaro, Giulio Metro, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Is gemcitabine cost effective in cancer treatment?Luca Toschi, Giovanna Finocchiaro, Giovanni Luca Ceresoli, et al.
Future Oncology (London, England)|March 6, 2024
Response to first-line pembrolizumab in metastatic <i>KRAS</i>-mutated non-small-cell lung cancerSabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Reviews on Recent Clinical Trials|April 9, 2008
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)Giulio Metro, Giovanna Finocchiaro, Luca Toschi, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Clinical Lung Cancer|August 15, 2019
Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant ChemotherapyAngelo Castello, Luca Toschi, Sabrina Rossi, et al.
Expert Review of Anticancer Therapy|December 22, 2022
Current treatment approaches for brain metastases in <i>ALK</i>/<i>ROS1</i>/<i>NTRK</i>-positive non-small-cell lung cancerSabrina Rossi, Arianna Marinello, Arianna Pagliaro, et al.
Nuclear Medicine Communications|April 3, 2018
Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancerAngelo Castello, Fabio Grizzi, Luca Toschi, et al.
Current Problems in Cancer|September 7, 2021
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLCSabrina Rossi, Paola Damiano, Luca Toschi, et al.
Cancers|December 23, 2023
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?Sabrina Rossi, Arianna Pagliaro, Angelica Michelini, et al.
Cancers|September 10, 2021
Subpopulations of Circulating Cells with Morphological Features of Malignancy Are Preoperatively Detected and Have Differential Prognostic Significance in Non-Small Cell Lung CancerEmanuela Fina, Davide Federico, Pierluigi Novellis, et al.
Critical Reviews in Oncology/Hematology|March 15, 2006
Clinical experience with gefitinib: an updateFederico Cappuzzo, Giovanna Finocchiaro, Giulio Metro, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Is gemcitabine cost effective in cancer treatment?Luca Toschi, Giovanna Finocchiaro, Giovanni Luca Ceresoli, et al.
Future Oncology (London, England)|March 6, 2024
Response to first-line pembrolizumab in metastatic <i>KRAS</i>-mutated non-small-cell lung cancerSabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Reviews on Recent Clinical Trials|April 9, 2008
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)Giulio Metro, Giovanna Finocchiaro, Luca Toschi, et al.
Pageof 5